HI
MRTX

HBK Investments’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

HBK Investments’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-26,000
Closed -$1.23M – 1473
2018
Q3 		$1.23M Buy
+26,000
New +$1.45M 0.01% 665

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

HBK Investments's MRTX Position: Q4 2018 in Review

HBK Investments sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2018, closing a stake of 26,000 shares — an estimated $1.23M sold.

HBK Investments first reported a position in MRTX in Q3 2018 and held it in 1 quarter. The position peaked at $1.23M in Q3 2018. 112 funds tracked by Wall St. Rank hold MRTX as of Q4 2018.

  • HBK Investments reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • HBK Investments sold 26,000 Mirati Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $1.23M.
  • HBK Investments first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • HBK Investments's Mirati Therapeutics, Inc. Common Stock position peaked at $1.23M in Q3 2018.
  • 112 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2018.

Based on HBK Investments's 13F filing for Q4 2018, filed 14 Feb 2019.